Prostate cancer for experts

May 17th - November 16th 2023

Aimed at:

Residents 4th and 5th year of Urology
4th year of O. Radiation therapy
4th and 5th year O. Medical
Associates of related specialties

COORDINATORS

Iván Henríquez López

Hospital Universitario Sant Joan, Reus

Oncology Radiation therapy.

Jesús Muñoz

Hospital Parc Tauli, Sabadell

Urology Service.

Enrique Gallardo

Hospital Parc Tauli, Sabadell

Medical Oncology Service.

FACULTY

Jaques Planas

María Isabel Chirivella

Marta Barrado

Digna Pachuca

Ángel Borque

Manuel Altabas

Asunción Hervás

Oscar Buisan

Luis Glaria Enriquez

Rafael García

Rodríguez Melcón

Enrique Sánchez Aparicio

Martínez Ballesteros

Alvaro Pinto

Felipe Couñago

Antonio Gómez Caamaño

Carmen González San Segundo

Antonio Conde Moreno

Fernando López Campos

David Buchse

Alejo Rodríguez-Vida

Ana Plata

Caterina Aversa

COURSE STRUCTURE

SECTION 1 - May 17th

From the basics to the clinical in prostate cancer

1.1. Functional anatomy of prostate cancer. – Urology. – Dr. J. Planas. H. Vall d’Hebron. Barcelona

1.2. Staging of prostate cancer. – O. Medicine – Dra. María Isabel Chirivella. H. La Fe. Valencia

1.3. Clinical prognostic factors in prostate cancer. – O. Radiation therapy – Dra. Marta Barrado. Complejo Hospitalario de Navarra. Pamplona

1.4. Use of conventional images and molecular in prostate cancer. – Radiology – Dra. Digna Pachuca. (México)

1.5. Screening and active surveillance. Current situation. – Urology – Dr. Ángel Borque. H. Miguel Servet. Zaragoza

SECTION 2 - June 14th

Standard treatment in prostate cancer

2.1. Radical prostatectomy. Techniques and indications.  – Urology – Por definir 

2.2. Dose Intensification of External Radiation Therapy with or without androgen deprivation. – O. Radiation therapy  – Dr. Manuel Altabas. H. Vall d’ Hebron. Barcelona 

2.3. Moderate hypofractionation in prostate cancer. – O. Radiation therapy – Dra. Asunción Hervás. Fundación Jimenez Díaz. Madrid 

2.4. Toxicity and quality of life of prostatectomy radical. – Urology –  Dr. Oscar Buisan. H. Germans Trias i Pujol. Badalona 

2.5. Toxicity and quality of life of external radiation therapy and androgen deprivation. – O. Radiation therapy – Dr. Luis Glaria Enriquez. H. La Paz. Madrid

SECTION 3 - July 12th

Specific treatments in prostate can

3.1. SBRT in prostate cancer. – O. Radiation therapy – Dr. Rafael García . H. Ruber Internacional. Madrid

3.2. Brachytherapy treatment (monotherapy) in prostate cancer. – O. Radiation therapy – Dr. Rodríguez Melcón. H. Negrín. Canarias 

3.3. Clinical management (cN0) in high risk prostate cancer. – O. Radiation therapy – Dr. Enrique Sánchez Aparicio. H. León. Castilla y León 

3.4. Clinical management (cN1 and pN1) in prostate cancer. – Urology – Dr. Martínez Ballesteros. H. Puerta Hierro. Madrid 

3.5. Adjuvant chemotherapy in high-risk prostate cancer. – O. Medical – Dr. Alvaro Pinto. H. La Paz. Madrid

SECTION 4 - August 9th

Special situations in prostate cancer

4.1. Genomic platforms in prostate cancer. – O. Radiation therapy – Dr. Felipe Couñago. H. Quirón Salud. Madrid 

4.2. Adjuvant radiation therapy and rescue radiation therapy. – O. Radiation therapy – Dr. Antonio Gómez Caamaño. H. Santiago de Compostela. Galicia 

4.3. Biochemical recurrence after radiotherapy. Treatment alternatives. – O. Radiation therapy – Dra. Carmen González San Segundo. H. Gregorio Marañón. Madrid 

4.4. Oligometastatic prostate cancer. Concepts and therapeutic approach. – O. Radiation therapy – Dr. Antonio Conde Moreno. IVO. Valencia 

4.5. Genomic markers in prostate cancer. – O. Radiation therapy – Dr. Fernando López Campos. Fundación Jimenez Díaz. Madrid

SECTION 5 - September 6th

New perspectives in advanced prostate cancer

5.1. Importance of local treatment in CaP hormone-sensitive metastatic. – O. Radiation therapy – Dr. David Buchser. H. Cruces. Bilbao 

5.2. Hormone-sensitive metastatic prostate cancer (CPHSm). Systemic management. – O. Medical – Dr. Alejo Rodríguez-Vida. H. del Mar. Barcelona 

5.3. Non-metastatic high-risk castration-resistant prostate cancer (CPRCM0). – Urology – Dra. Ana Plata. H. Tenerife. Canarias 

5.4. Metastatic castration-resistant prostate cancer (CPRCM1). – O. Medical – Dra Caterina Aversa. H. Clínic. Barcelona 

5.5. Future of Prostate Cancer. – Drs course Coordinators

INFORMATION

REGISTRATION
Hands on course: 1.200€
CONTACT

Aventik Medical S.L.U.
Tel. 685265622
info@aventik.es